18th March, 2020 / Covid-19 statement

Dear customer,

The situation surrounding the outbreak of Covid-19 is rapidly changing and it is resulting in challenges for organisations across the world. As a business we are continually monitoring the latest information and local advice about the global COVID-19 outbreak and we are taking measures to ensure we safeguard the health of our employees and maintain business continuity. We have established Covid-19 Teams to oversee our response to the virus and our contingency planning. 

These teams are:

1. actively monitoring disease progression in each country, WHO guidance, supplier and supply chain risks and prevention and containment measures;

2. communicating best practices for safeguarding colleague health and ensuring that anyone displaying symptoms follows local guidance for seeking treatment and self-isolation;

3. testing business contingency plans and building stock to ensure that we can maintain supply and delivery.

Our manufacturing sites, offices and labs are continuing to work, subject to any local restrictions. We have identified areas which we consider critical to operate and within these areas, we have developed operational continuity plans in our teams to preserve our ability to supply our valued customers over the coming months.

We have been taking additional measures to help prevent infections at our facilities in Lawrenceville, GA and Cardiff, UK. We are implementing policies to protect all our employees and help minimise the spread of the virus. These include, where possible, enabling employees to work from home, restricting visitors and ‘in-person’ meetings at our sites and cancelling attendance to large group gatherings and encouraging our teams to utilise technology as a substitute for in-person meetings.  We have also implemented staff travel restrictions and banned business air travel. At all times we are complying with all local safety standards and guidance as a minimum and exceeding these as we think appropriate.

Genesis Biosciences will continue to take appropriate measures during this event to ensure our operations both in the USA and Europe continue running. Our global supply chain teams are working to identify any potential impact on our raw material supplies and are putting plans in place to help ensure continued supply. We have already completed an initial review of our supply chains and will monitor these as the situation develops, putting contingency plans in place as required.

We currently have good stocks of raw materials across all our sites, our customer orders have not been impacted at the time being. However, this is a dynamic situation and our commercial and production teams are working to identify any potential impacts and we will work closely with customers should shortages or logistics complexity affect any deliveries in the weeks ahead.

We are confident in our preparation and contingency planning for situations such as this. Please be assured that we are committed to caring for our customers at all times and will continue to monitor the situation as it develops and adapt our processes and procedures to fulfil our commitments as your supplier and to keep all of our stakeholders safe and healthy at this challenging time.

Thank you,

Conrad Mielcuszny, CEO

If you have any queries at all, please do not hesitate to get in touch.

Phone +44 (0)29 2079 1185
Fax +44 (0)29 2036 2831
Email info@genesisbiosciences.com

Leave a Reply

Your email address will not be published. Required fields are marked *